Table 2 Univariate analysis
Parameter | Median OS in months (CI 95 %) | P-value |
|---|---|---|
Initial characteristics | ||
Tumor biology group | <0.001 | |
HER2+ HR+ | 32.1 (16.5 – NC) | |
HER2+ HR- | 28.7 (19.1–34.5) | |
HER2- HR+ | 12.5 (10.4–22.8) | |
Triple negative | 7.6 (4.6–10.4) | |
ER status | 0.087 | |
Negative | 13.3 (10.0–19.1) | |
Positive | 20.1 (12.4–20.6) | |
PR status | 0.035 | |
Negative | 12.5 (10.6–17.8) | |
Positive | 22.8 (16.5–35.6) | |
HER2 status | <0.001 | |
Negative | 10.4 (8.5–12.5) | |
Positive | 31.6 (20.2–34.5) | |
Histological subtype | 0.344 | |
Ductal carcinoma | 15.2 (11.6–20.6) | |
All other subtypes | 20.1 (10.1–35.6) | |
Histological grade (SBR) | 0.024 | |
1 or 2 | 20.6 (14.8–31.6) | |
3 | 11.1 (9.7–15.5) | |
Inflammatory BC | 0.523 | |
No | 15.1 (11.6–20.2) | |
Yes | 20.9 (6.8 – NC) | |
Metastatic status at BC diagnosis | 0.012 | |
M0 | 13.6 (10.4–16.5) | |
M1 | 27.2 (13.7–32.1) | |
Characteristics at the time of the serum sample | ||
Age group | 0.723 | |
< 50 | 15.0 (10.0–23.0) | |
50 to 70 | 16.3 (11.6–20.7) | |
> 70 | 20.2 (9.7–51.4) | |
ECOG status | <0.001 | |
Score 0 | 34.5 (20.9–53.4) | |
Score 1 | 16.5 (12.1–22.5) | |
Score 2 | 8.5 (3.8–16.8) | |
Score 3 | 2.0 (1.4–4.6) | |
Number of lines of CT | <0.001 | |
0 line | 17.6 (14.8–27.2) | |
1 or 2 line(s) | 22.8 (16.8–32.1) | |
> 2 lines | 6.4 (4.6–10.4) | |
Previous anti-HER2 treatment | <0.001 | |
No | 11.7 (9.8–15.2) | |
Yes | 28.7 (20.1–33.9) | |
Metastatic-free interval | 0.464 | |
≤ 24 months | 14.8 (10.6–20.7) | |
> 24 months | 16.5 (12.4–23.3) | |
Number of metastatic sites | <0.001 | |
1 | 59.2 (23.0 – NC) | |
> 2 | 13.3 (11.1–16.8) | |
Location of metastatic sites | 0.001 | |
Bone and/or subcutaneous only | 63.6 (95 % CI NC) | |
Visceral | 14.4 (11.4–19.4) | |
Brain metastases | <0.001 | |
Absent | 30.4 (17.2–34.9) | |
Present | 9.7 (5.6–10.4) | |
Liver metastases | <0.001 | |
Absent | 28.7 (14.9–36.8) | |
Present | 12.4 (10.6–17.6) | |
Bone metastases | 0.639 | |
Absent | 17.8 (10.6–31.6) | |
Present | 15.2 (12.1–20.2) | |
Lung metastases | 0.096 | |
Absent | 20.7 (14.4–30.4) | |
Present | 12.4 (10.1–17.8) | |
Lymph node metastases | 0.296 | |
Absent | 19.4 (12.4–27.7) | |
Present | 13.6 (10.5–19.1) | |
Subcutaneous metastases | 0.006 | |
Absent | 19.4 (13.7–22.8) | |
Present | 11.3 (4.7–15.2) | |
Pleural metastases | 0.077 | |
Absent | 16.3 (12.5–20.9) | |
Present | 13.3 (5.2–28.7) | |
Metastases of other sites | <0.001 | |
Absent | 20.9 (16.2–30.7) | |
Present | 11.1 (7.5–13.6) | |
Anemia | 0.134 | |
No | 15.5 (8.1–22.8) | |
Yes | 10.3 (8.1–11.7) | |
Leucopenia | 0.363 | |
No | 10.3 (8.5–12.4) | |
Yes | 10.8 (6.4–31.6) | |
Neutropenia | 0.908 | |
No | 10.6 (8.5–12.4) | |
Yes | 10.4 (5.2 – NC) | |
Lymphopenia | 0.351 | |
No | 11.1 (9.4–15.5) | |
Yes | 8.4 (4.7–10.6) | |
Thrombopenia | 0.748 | |
No | 10.6 (8.5–13.6) | |
Yes | 10.1 (2.6–20.6) | |
Serum protein level | 0.780 | |
Normal | 9.7 (5.2–11.6) | |
Low | 6.4 (2.3–13.6) | |
Serum albumin level | <0.001 | |
Normal | 14.4 (11.1–19.4) | |
Low | 1.6 (1.1–2.4) | |
Serum LDH | 0.241 | |
Normal | 10.3 (5.5–13.7) | |
Elevated | 4.7 (1.9–9.8) | |
Elevated CEA | 0.001 | |
Normal | 20.6 (16.2–28.7) | |
Elevated | 10.6 (8.7–12.5) | |
Elevated CA 15-3 | <0.001 | |
Normal | 28.7 (20.1–59.2) | |
Elevated | 11.3 (9.7–14.4) | |
Serum HER2 (cut-off 15 ng/mL) | <0.001 | |
Normal | 22.6 (16.2–32.3) | |
Elevated | 11.3 (8.9–14.4) | |
Serum HER2 (cut-off 30 ng/mL) | <0.001 | |
Normal | 20.2 (15.0–28.6) | |
Elevated | 10.1 (5.2–13.6) | |
Serum NSE (cut-off 12.5 μg/L) | <0.001 | |
Normal | 20.6 (16.2–30.4) | |
Elevated | 9.9 (5.6–14.4) | |
Serum MMP9 (cut-off 50 ng/mL) | 0.009 | |
Normal | 3.8 (1.1 – NC) | |
Elevated | 16.2 (12.5–20.7) | |
Serum S100ß (cut-off 0.12 μg/L) | <0.001 | |
Normal | 17.2 (14.4–22.6) | |
Elevated | 4.5 (1.6–10.0) | |
Serum S100ß (cut-off 0.072 μg/L) | <0.001 | |
Normal | 20.3 (15.1–30.4) | |
Elevated | 6.2 (4.5–12.1) | |